Further to DrugAlert vol 966 and vol 990, HPS Pharmacies wishes to advise that Novo Nordisk is discontinuing the following insulin products:
Product to be discontinued | Planned discontinuation date | Potential alternatives available |
Fiasp® (insulin aspart)
|
March 2025 (pen)
December 2024 (vials) |
Fiasp® (insulin aspart) Penfill® cartridge |
Ryzodeg® (Insulin degludec + insulin aspart 70/30)
|
February 2025 | Ryzodeg® (Insulin degludec + insulin aspart 70/30) Penfill® cartridge |
Actrapid® (insulin neutral)
|
December 2026 |
|
Protaphane® (insulin isophane)
|
February 2025 (Innolet®)
December 2026 (Penfill®) |
|
Levemir® (insulin detemir)
|
December 2026 | No other insulin detemir products available.
Alternative long-acting insulin may be considered on a case-by-case basis. |
The Therapeutic Goods Administration (TGA) has implemented a Serious Scarcity Substitution Instrument (SSSI) for Protaphane® InnoLet® and Ryzodeg® FlexTouch®. This allows pharmacists to substitute the presentation form of the unavailable product, providing the conditions of the SSSI are met.
Further information about these supply changes can be found on the TGA website. The Australian Commission on Safety and Quality in Health Care has also produced guidance for clinicians. This details important safety considerations when changing insulin products.
Reminder: insulin is a high-risk medication commonly involved in incidents resulting in serious harm.
Retain this notice in a prominent position, including in other related business units for at least one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Novo Nordisk on 1800 668 626 or your pharmacist at HPS Pharmacies.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates